Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395012 · ClinicalTrials.gov registry record · Phase 1
A First-In-Human Study of LY3985297 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT06395012 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 140 participants.
The verdict
NCT06395012, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it. The study is conducted in two parts (part A and B), each part has a separate treatment cohort. The study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.
Interventions
- DRUG Placebo
- DRUG LY3985297
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2025-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06395012
The ClinicalTrials.gov registry entry for NCT06395012 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06395012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06395012 about?
NCT06395012 is a clinical study titled "A First-In-Human Study of LY3985297 in Healthy Participants". The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of th...
What is the current status of trial NCT06395012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-06-07. Estimated completion is 2025-08-06.
What interventions are being tested in trial NCT06395012?
The interventions under investigation include: Placebo (DRUG), LY3985297 (DRUG).
Who is sponsoring clinical trial NCT06395012?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.